文献速递糖尿病

1型糖尿病合并严重低血糖或肾移植后血糖控制不佳患者:胰岛移植与胰岛素治疗的随机对照试验(TRIMECO)

Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2018-05-15

TRIMECO多中心开放标签随机对照试验纳入50例1型糖尿病伴严重低血糖或肾移植后血糖控制不佳患者,比较立即胰岛移植与强化胰岛素治疗。6个月时胰岛移植组64%患者改良β评分≥6,胰岛素组为0%(p<0.0001)。胰岛移植有效改善代谢结局,但免疫抑制可能影响肾功能,需谨慎选择患者。

要点

  • 6个月时改良β评分≥6者:胰岛移植组64%(16/25)vs 胰岛素组0%(0/22),p<0.0001。
  • 首次输注后12个月,55次输注中4次(7%)发生出血并发症。
  • 未接受肾移植的胰岛受者中位肾小球滤过率从90.5降至71.8 mL/min。

核心结论

  • 对于本研究评估的适应症,胰岛移植有效改善代谢结局。
  • 胰岛移植似乎是严重、不稳定且对强化内科治疗无反应的1型糖尿病患者的有效选择,但免疫抑制可影响肾功能,需谨慎选择患者。

研究设计与样本

  • 多中心、开放标签、随机对照试验,15所大学医院参与,1:1随机分配至立即胰岛移植组或强化胰岛素治疗组(后续可延迟胰岛移植)。
  • 纳入18-65岁伴严重低血糖或低血糖感知缺陷、或肾移植后血糖控制不佳的1型糖尿病患者。
  • 胰岛受者计划接受每公斤体重11000胰岛当量,分1至3次输注。
  • 主要结局为首次胰岛输注后6个月(立即移植组)或随机化后6个月(胰岛素组)改良β评分≥6的患者比例。
  • 2010年7月8日至2013年7月29日共随机分配50例患者(立即胰岛移植组n=26,胰岛素治疗组n=24),其中3例未接受分配干预。

主要发现

  • 6个月时,立即胰岛移植组25例中16例(64%[95%CI 43-82])改良β评分≥6,胰岛素组22例中0例(0%[0-15]),p<0.0001。
  • 立即移植组中位随访184天(IQR 181-186),胰岛素组185天(IQR 172-201)。
  • 首次输注后12个月,55次输注中发生4次(7%[95%CI 2-18])出血并发症。
  • 未接受肾移植的胰岛受者中位肾小球滤过率从90.5 mL/min(IQR 76.6-94.0)降至71.8 mL/min(IQR 59.0-89.0)。
  • 既往接受肾移植的胰岛受者中位肾小球滤过率从63.0 mL/min(IQR 55.0-71.0)降至57.0 mL/min(IQR 45.5-65.1)。

临床怎么用

  • 作者认为,对于严重、不稳定且对强化内科治疗无反应的1型糖尿病患者,胰岛移植似乎是有效选择,但免疫抑制可影响肾功能,需谨慎选择患者。
  • 原文未据此给出具体推荐。

局限性

  • 需要更长期随访的研究。
  • 免疫抑制可影响肾功能,需谨慎选择患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Islet transplantation is indicated for patients with type 1 diabetes with severe hypoglycaemia or after kidney transplantation. We did a randomised trial to assess the efficacy and safety of islet transplantation compared with insulin therapy in these patients. METHODS: In this multicentre, open-label, randomised controlled trial, we randomly assigned (1:1) patients with type 1 diabetes at 15 university hospitals to receive immediate islet transplantation or intensive insulin therapy (followed by delayed islet transplantation). Eligible patients were aged 18-65 years and had severe hypoglycaemia or hypoglycaemia unawareness, or kidney grafts with poor glycaemic control. We used computer-generated randomisation, stratified by centre and type of patient. Islet recipients were scheduled to receive 11 000 islet equivalents per kg bodyweight in one to three infusions. The primary outcome was proportion of patients with a modified β-score (in which an overall score of 0 was not allocated when stimulated C-peptide was negative) of 6 or higher at 6 months after first islet infusion in the immediate transplantation group or 6 months after randomisation in the insulin group. The primary analysis included all patients who received the allocated intervention; safety was assessed in all patients who received islet infusions. This trial is registered with ClinicalTrials.gov, number NCT01148680, and is completed. FINDINGS: Between July 8, 2010, and July 29, 2013, 50 patients were randomly assigned to immediate islet transplantation (n=26) or insulin treatment (n=24), of whom three (one in the immediate islet transplantation group and two in the insulin therapy group) did not receive the allocated intervention. Median follow-up was 184 days (IQR 181-186) in the immediate transplantation group and 185 days (172-201) in the insulin therapy group. At 6 months, 16 (64% [95% CI 43-82]) of 25 patients in the immediate islet transplantation group had a modified β-score of 6 or higher versus none (0% [0-15]) of the 22 patients in the insulin group (p<0·0001). At 12 months after first infusion, bleeding complications had occurred in four (7% [2-18]) of 55 infusions, and a decrease in median glomerular filtration rate from 90·5 mL/min (IQR 76·6-94·0) to 71·8 mL/min (59·0-89·0) was observed in islet recipients who had not previously received a kidney graft and from 63·0 mL/min (55·0-71·0) to 57·0 mL/min (45·5-65·1) in islet recipients who had previously received a kidney graft. INTERPRETATION: For the indications assessed in this study, islet transplantation effectively improves metabolic outcomes. Although studies with longer-term follow-up are needed, islet transplantation seems to be a valid option for patients with severe, unstable type 1 diabetes who are not responding to intensive medical treatments. However, immunosuppression can affect kidney function, necessitating careful selection of patients. FUNDING: Programme Hospitalier de Recherche Clinique grant from the French Government.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Lablanche S, Vantyghem MC, Kessler L, et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2018. PMID: 29776895. doi:10.1016/S2213-8587(18)30078-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。